Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (55) 55
oncology (55) 55
female (52) 52
index medicus (52) 52
breast cancer (51) 51
breast neoplasms - drug therapy (35) 35
chemotherapy (34) 34
middle aged (34) 34
adult (32) 32
breast neoplasms - pathology (31) 31
aged (26) 26
disease-free survival (22) 22
cancer (20) 20
metastasis (20) 20
therapy (19) 19
treatment outcome (19) 19
tumors (19) 19
antineoplastic combined chemotherapy protocols - therapeutic use (18) 18
cancer therapies (18) 18
survival (18) 18
care and treatment (14) 14
trastuzumab (14) 14
antineoplastic combined chemotherapy protocols - adverse effects (13) 13
drug therapy (12) 12
endocrine therapy (12) 12
erbb-2 protein (12) 12
patients (12) 12
analysis (11) 11
breast neoplasms - mortality (11) 11
efficacy (11) 11
medicine & public health (11) 11
paclitaxel (11) 11
research (11) 11
studies (11) 11
breast neoplasms - genetics (10) 10
chemotherapy, adjuvant (10) 10
docetaxel (10) 10
drug administration schedule (10) 10
estrogen (10) 10
metastases (10) 10
postmenopausal women (10) 10
prognosis (10) 10
tamoxifen (10) 10
aged, 80 and over (9) 9
antineoplastic agents - therapeutic use (9) 9
clinical trials (9) 9
kaplan-meier estimate (9) 9
male (9) 9
time factors (9) 9
breast tumors (8) 8
combination (8) 8
dose-response relationship, drug (8) 8
follow-up studies (8) 8
hematology, oncology and palliative medicine (8) 8
women (8) 8
antibodies, monoclonal, humanized - administration & dosage (7) 7
antineoplastic agents, hormonal - therapeutic use (7) 7
breast neoplasms - surgery (7) 7
capecitabine (7) 7
cyclophosphamide (7) 7
genes (7) 7
her2 (7) 7
medicine (7) 7
medicine, general & internal (7) 7
mutation (7) 7
post-menopause (7) 7
proportional hazards models (7) 7
surgery (7) 7
survival analysis (7) 7
womens health (7) 7
abridged index medicus (6) 6
antibodies, monoclonal, humanized - adverse effects (6) 6
antimitotic agents (6) 6
antineoplastic agents (6) 6
antineoplastic agents - adverse effects (6) 6
aromatase inhibitors - adverse effects (6) 6
biomarkers (6) 6
breast (6) 6
breast neoplasms - metabolism (6) 6
epidermal growth factor (6) 6
fluorouracil - administration & dosage (6) 6
gene expression (6) 6
gene expression profiling (6) 6
infusions, intravenous (6) 6
maximum tolerated dose (6) 6
metastatic breast cancer (6) 6
multidisciplinary sciences (6) 6
patient outcomes (6) 6
proteomics (6) 6
science (6) 6
toxicity (6) 6
adjuvant chemotherapy (5) 5
androstadienes - administration & dosage (5) 5
animals (5) 5
aromatase (5) 5
aromatase inhibitors (5) 5
article (5) 5
biomarkers, tumor - analysis (5) 5
breast neoplasms - chemistry (5) 5
cancers and neoplasms (5) 5
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Targeting the PI3K/AKT/mTOR pathway in estrogen receptor-positive breast cancer
by Ciruelos Gil, Eva Maria
Cancer Treatment Reviews, ISSN 0305-7372, 2014, Volume 40, Issue 7, pp. 862 - 871
Abstract Approximately 70−75% of breast cancers express the estrogen receptor (ER), indicating a level of dependence on estrogen for growth. Endocrine therapy... 
Hematology, Oncology and Palliative Medicine | Estrogen receptor | Endocrine resistance | PI3K | Mammalian target of rapamycin | mTOR | Endocrine therapy | Luminal type | Breast cancer | AKT | Phosphatidylinositol 3-kinase | MTOR | PIK3CA MUTATIONS | INHIBITOR EVEROLIMUS | ONCOLOGY | RANDOMIZED PHASE-II | POOR-PROGNOSIS | PI3K PATHWAY | ANTIESTROGEN RESISTANCE | PHOSPHATIDYLINOSITOL 3-KINASE PATHWAY | PROGESTERONE-RECEPTOR | POSTMENOPAUSAL WOMEN | Receptors, Estrogen - metabolism | Signal Transduction - drug effects | TOR Serine-Threonine Kinases - metabolism | Humans | Female | Antineoplastic Agents - therapeutic use | Molecular Targeted Therapy | Proto-Oncogene Proteins c-akt - metabolism | Breast Neoplasms - drug therapy | Phosphatidylinositol 3-Kinase - metabolism | Breast Neoplasms - metabolism | Phenols | Development and progression | Chemotherapy | Estrogen | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study
by Swain, Sandra M, Dr and Kim, Sung-Bae, MD and Cortés, Javier, MD and Ro, Jungsil, MD and Semiglazov, Vladimir, MD and Campone, Mario, MD and Ciruelos, Eva, MD and Ferrero, Jean-Marc, MD and Schneeweiss, Andreas, MD and Knott, Adam, PhD and Clark, Emma, MSc and Ross, Graham, FFPM and Benyunes, Mark C, MD and Baselga, José, MD
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 6, pp. 461 - 471
Summary Background CLEOPATRA is a phase 3 study to compare the efficacy and safety of pertuzumab, trastuzumab, and docetaxel with placebo, trastuzumab, and... 
Hematology, Oncology and Palliative Medicine | ADJUVANT CHEMOTHERAPY | TRIAL | PLUS DOCETAXEL | COMPLEX | MULTICENTER | ONCOLOGY | HERCEPTIN | RECEPTOR | MONOCLONAL-ANTIBODY | OPEN-LABEL | HER2 | Double-Blind Method | Humans | Middle Aged | Kaplan-Meier Estimate | Proportional Hazards Models | Receptor, ErbB-2 - metabolism | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Treatment Outcome | Breast Neoplasms - drug therapy | Disease-Free Survival | Taxoids - administration & dosage | Breast Neoplasms - enzymology | Antibodies, Monoclonal, Humanized - administration & dosage | Time Factors | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Intention to Treat Analysis | Biomarkers, Tumor - metabolism | Breast Neoplasms - mortality | Female | Receptor, ErbB-2 - antagonists & inhibitors | Biomarkers, Tumor - antagonists & inhibitors | Molecular Targeted Therapy - methods | Trastuzumab | Patient outcomes | Analysis | Oncology, Experimental | Breast cancer | Metastasis | Research | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort
by Gianni, Luca, Dr and Eiermann, Wolfgang, MD and Semiglazov, Vladimir, MD and Manikhas, Alexey, MD and Lluch, Ana, MD and Tjulandin, Sergey, MD and Zambetti, Milvia, MD and Vazquez, Federico, MD and Byakhow, Mikhail, MD and Lichinitser, Mikhail, MD and Climent, Miguel Angel, MD and Ciruelos, Eva, MD and Ojeda, Belén, MD and Mansutti, Mauro, MD and Bozhok, Alla, MD and Baronio, Roberta, MSci and Feyereislova, Andrea, MD and Barton, Claire, MD and Valagussa, Pinuccia and Baselga, Jose, MD
Lancet, The, ISSN 0140-6736, 2010, Volume 375, Issue 9712, pp. 377 - 384
Summary Background The monoclonal antibody trastuzumab has survival benefit when given with chemotherapy to patients with early, operable, and metastatic... 
Internal Medicine | PHASE-III TRIAL | MEDICINE, GENERAL & INTERNAL | THERAPY | EFFICACY | CYCLOPHOSPHAMIDE | SAFETY | RECEPTOR | MONOCLONAL-ANTIBODY | COMPARING DOXORUBICIN | PACLITAXEL | PLUS | Cyclophosphamide - administration & dosage | Adenocarcinoma - pathology | Prospective Studies | Follow-Up Studies | Humans | Middle Aged | Antibodies, Monoclonal - therapeutic use | Antibodies, Monoclonal, Humanized | Fluorouracil - administration & dosage | Time Factors | Adult | Female | Neoadjuvant Therapy | Chemotherapy, Adjuvant | Paclitaxel - administration & dosage | Receptor, ErbB-2 - drug effects | Doxorubicin - administration & dosage | Proportional Hazards Models | Combined Modality Therapy | Adenocarcinoma - drug therapy | Breast Neoplasms - drug therapy | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Genes, erbB-2 - genetics | Methotrexate - administration & dosage | Infusions, Intravenous | Trastuzumab | Chemotherapy | Breast cancer | Womens health | Cancer therapies
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort
by Gianni, Luca, Dr and Eiermann, Wolfgang, MD and Semiglazov, Vladimir, MD and Lluch, Ana, PhD and Tjulandin, Sergei, MD and Zambetti, Milvia, MD and Moliterni, Angela, MD and Vazquez, Federico, MD and Byakhov, Mikhail J, PhD and Lichinitser, Mikhail, MD and Climent, Miguel Angel, MD and Ciruelos, Eva, MD and Ojeda, Belen, MD and Mansutti, Mauro, MD and Bozhok, Alla, PhD and Magazzù, Domenico, PhD and Heinzmann, Dominik, PhD and Steinseifer, Jutta, PhD and Valagussa, Pinuccia, BS and Baselga, Jose, MD
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 6, pp. 640 - 647
Summary Background In our randomised, controlled, phase 3 trial NeOAdjuvant Herceptin (NOAH) trial in women with HER2-positive locally advanced or inflammatory... 
Hematology, Oncology and Palliative Medicine | PREDICTS | INVERSE PROBABILITY | THERAPY | CLINICAL-TRIAL | ONCOLOGY | IMPROVED SURVIVAL | CHEMOTHERAPY | PATHOLOGICAL COMPLETE RESPONSE | Antibodies, Monoclonal, Humanized - adverse effects | Follow-Up Studies | Inflammatory Breast Neoplasms - pathology | Humans | Middle Aged | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Antineoplastic Agents - administration & dosage | Breast Neoplasms - drug therapy | Disease-Free Survival | Antibodies, Monoclonal, Humanized - administration & dosage | Antineoplastic Agents - adverse effects | Breast Neoplasms - pathology | Genes, erbB-2 | Inflammatory Breast Neoplasms - drug therapy | Adult | Breast Neoplasms - mortality | Female | Neoadjuvant Therapy | Aged | Chemotherapy, Adjuvant | Trastuzumab | Inflammatory Breast Neoplasms - mortality | Antimitotic agents | Care and treatment | Breast cancer | Antineoplastic agents | Analysis | Chemotherapy | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
by Swain, Sandra M and Baselga, José and Kim, Sung-Bae and Ro, Jungsil and Semiglazov, Vladimir and Campone, Mario and Ciruelos, Eva and Ferrero, Jean-Marc and Schneeweiss, Andreas and Heeson, Sarah and Clark, Emma and Ross, Graham and Benyunes, Mark C and Cortés, Javier and CLEOPATRA Study Grp and CLEOPATRA Study Group
The New England Journal of Medicine, ISSN 0028-4793, 02/2015, Volume 372, Issue 8, pp. 724 - 734
In a randomized trial comparing pertuzumab, trastuzumab, and docetaxel with placebo, trastuzumab, and docetaxel, the pertuzumab combination resulted in a... 
SURVIVAL | MEDICINE, GENERAL & INTERNAL | PHASE-II TRIAL | PLUS DOCETAXEL | THERAPY | EFFICACY | TOLERABILITY | DOUBLE-BLIND | RECEPTOR | CLEOPATRA | COMBINATION | Antibodies, Monoclonal, Humanized - adverse effects | Double-Blind Method | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Breast Neoplasms - drug therapy | Taxoids - administration & dosage | Antibodies, Monoclonal, Humanized - administration & dosage | Neoplasm Metastasis - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Survival Analysis | Adult | Breast Neoplasms - mortality | Female | Aged | Receptor, ErbB-2 | Infusions, Intravenous | Trastuzumab | Care and treatment | Pertuzumab | Docetaxel | Breast cancer | Dosage and administration | Diagnosis | Research | Chemotherapy | Epidermal growth factor | Survival | ErbB-2 protein | Clinical outcomes | Metastases
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial
by von Minckwitz, Gunter, Prof and Puglisi, Fabio, MD and Cortes, Javier, MD and Vrdoljak, Eduard, Prof and Marschner, Norbert, MD and Zielinski, Christoph, Prof and Villanueva, Cristian, MD and Romieu, Gilles, MD and Lang, István, Prof and Ciruelos, Eva, MD and De Laurentiis, Michele, MD and Veyret, Corinne, Prof and de Ducla, Sabine, DEA and Freudensprung, Ulrich, MSc and Srock, Stefanie, MD and Gligorov, Joseph, MD
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 11, pp. 1269 - 1278
Summary Background Combining bevacizumab with first-line or second-line chemotherapy improves progression-free survival in HER2-negative locally recurrent or... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | THERAPY | EFFICACY | ONCOLOGY | GROWTH | COMBINATION | CONTINUATION | DISEASE PROGRESSION | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Follow-Up Studies | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Neoplasm Recurrence, Local - drug therapy | Neoplasm Recurrence, Local - mortality | Bevacizumab | Patient Selection | Dose-Response Relationship, Drug | Neoplasm Recurrence, Local - pathology | Antibodies, Monoclonal, Humanized - administration & dosage | Time Factors | Neoplasm Invasiveness - pathology | Adult | Remission Induction - methods | Antibodies, Monoclonal, Humanized - adverse effects | Drug Administration Schedule | Treatment Outcome | Breast Neoplasms - drug therapy | Disease-Free Survival | Retreatment | Maximum Tolerated Dose | Breast Neoplasms - genetics | Breast Neoplasms - pathology | Genes, erbB-2 - genetics | Survival Analysis | Breast Neoplasms - mortality | Aged | Neoplasm Staging | Medical colleges | Care and treatment | Relapse | Chemotherapy | Breast cancer | Metastasis | Angiogenesis inhibitors | Diseases | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial
by Colleoni, Marco and Luo, Weixiu and Karlsson, Per and Chirgwin, Jacquie and Aebi, Stefan and Jerusalem, Guy and Neven, Patrick and Hitre, Erika and Graas, Marie-Pascale and Simoncini, Edda and Kamby, Claus and Thompson, Alastair and Loibl, Sibylle and Gavilá, Joaquín and Kuroi, Katsumasa and Marth, Christian and Müller, Bettina and O'Reilly, Seamus and Di Lauro, Vincenzo and Gombos, Andrea and Ruhstaller, Thomas and Burstein, Harold and Ribi, Karin and Bernhard, Jürg and Viale, Giuseppe and Maibach, Rudolf and Rabaglio-Poretti, Manuela and Gelber, Richard D and Coates, Alan S and Di Leo, Angelo and Regan, Meredith M and Goldhirsch, Aron and Vandebroek, An and Berliere, Martine and Mitine, Carine and Vuylsteke, Peter and Borms, Marleen and D'Hondt, Randal and Glorieux, Philippe and Mebis, Jeroen and Verhoeven, Didier and Coibion, Michael and Forget, Frederic and Duck, Lionel and Wyendaele, Wim and Barbeaux, Annelore and Salmon, Jean-Paul and Berteloot, Patrick and Vermeij, Joanna and Richard, Vincent and Cinieri, Saverio and Gianni, Lorenzo and Clerico, Mario and Pinotti, Graziella and Bernardo, Antonio and Biganzoli, Leo and Gennari, Alessandra and Graiff, Claudio and Amadori, Dino and Passalacqua, Rodolfo and Forbes, John and Francis, Prudence and Foo, Serene and Boyle, Frances and Redfern, Andrew and van der Westhuizen, Andre and Lewis, Craig and Sharma, Ravi and Sharma, Sharad and Beale, Philip and Byard, Ian and Begbie, Stephen and Sardelic, Frank and Abdi, Ehtesham and Clark, David and Chindewere, Aaron and Della-Fiorentina, Stephen and Asghari, Ray and Islam, Mohammed and Na Teo, Lee and White, Shane and Gilbert, Linda and Gardner, Katherine and Uhlmann, Catarina and Rauch, Daniel and Mannhart, Meinrad and Buser, Katharina and Dedes, Konstantin and Mueller, Andreas and Rageth, Christoph and Von Orelli, Stephanie and Senn, Hans Joerg and Pagani, Olivia and Pedrazzini, Augusto and Rochlitz, Christoph and Bodmer, Alexandre and Anchisi, Sandro and Zaman, Khalil and von Moos, Roger and Betticher, Daniel and ... and SOLE Investigators and Institute of Clinical Sciences, Department of Oncology and Sahlgrenska akademin and Göteborgs universitet and Gothenburg University and Sahlgrenska Academy and Institutionen för kliniska vetenskaper, Avdelningen för onkologi
The Lancet Oncology, ISSN 1470-2045, 01/2018, Volume 19, Issue 1, pp. 127 - 138
In animal models of breast cancer, resistance to continuous use of letrozole can be reversed by withdrawal and reintroduction of letrozole. We therefore... 
CELLS | THERAPY | MODEL | ONCOLOGY | TERM ESTROGEN DEPRIVATION | TAMOXIFEN | Triazoles - administration & dosage | Triazoles - adverse effects | Humans | Middle Aged | Receptors, Estrogen - analysis | Antineoplastic Agents - administration & dosage | Nitriles - administration & dosage | Receptors, Progesterone - analysis | Aromatase Inhibitors - adverse effects | Breast Neoplasms - chemistry | Time Factors | Antineoplastic Agents - adverse effects | Postmenopause | Female | Chemotherapy, Adjuvant | Aromatase Inhibitors - administration & dosage | Drug Administration Schedule | Biomarkers, Tumor - analysis | Treatment Outcome | Breast Neoplasms - drug therapy | Disease-Free Survival | Breast Neoplasms - pathology | Breast Neoplasms - mortality | Aged | Receptor, ErbB-2 - analysis | Nitriles - adverse effects | Letrozole | Antimitotic agents | Breast cancer | Product development | Postmenopausal women | Antineoplastic agents | Analysis | pathology | Estrogen | Breast Neoplasms | Receptors | administration & dosage | Triazoles | Tumor | Nitriles | Adjuvant | chemistry | ErbB-2 | drug therapy | Antineoplastic Agents | analysis | Aromatase Inhibitors | Chemotherapy | Receptor | adverse effects | Biomarkers | mortality | Progesterone | Cancer and Oncology | Cancer och onkologi
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial
by Cortés, Javier, Dr and Dieras, Véronique, MD and Ro, Jungsil, MD and Barriere, Jérôme, MD and Bachelot, Thomas, MD and Hurvitz, Sara, MD and Le Rhun, Emilie, MD and Espié, Marc, MD and Kim, Sung-Bae, MD and Schneeweiss, Andreas, MD and Sohn, Joo Hyuk, MD and Nabholtz, Jean-Marc, Prof and Kellokumpu-Lehtinen, Pirkko-Liisa, Prof and Taguchi, Julie, MD and Piacentini, Federico, MD and Ciruelos, Eva, MD and Bono, Petri, MD and Ould-Kaci, Mahmoud, MD and Roux, Flavien, MSc and Joensuu, Heikki, Prof
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 16, pp. 1700 - 1710
Summary Background Patients with advanced HER2-positive breast cancer frequently develop CNS metastases. The metastases that progress after brain radiotherapy... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | CAPECITABINE | BIBW 2992 | EFFICACY | ONCOLOGY | MUTATIONS | ERBB FAMILY BLOCKER | United States | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Protein Kinase Inhibitors - adverse effects | Vinblastine - therapeutic use | Brain Neoplasms - secondary | Breast Neoplasms - chemistry | Time Factors | Vinblastine - analogs & derivatives | Vinblastine - adverse effects | Adult | Female | Receptor, ErbB-2 - antagonists & inhibitors | Brain Neoplasms - mortality | Antineoplastic Agents, Phytogenic - therapeutic use | Biomarkers, Tumor - antagonists & inhibitors | Republic of Korea | Antineoplastic Agents, Phytogenic - adverse effects | Brain Neoplasms - chemistry | Trastuzumab - therapeutic use | Biomarkers, Tumor - analysis | Europe | Risk Factors | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Brain Neoplasms - drug therapy | Breast Neoplasms - drug therapy | Disease Progression | Canada | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Quinazolines - adverse effects | Breast Neoplasms - mortality | Receptor, ErbB-2 - analysis | Antimitotic agents | Medical colleges | Care and treatment | Breast cancer | Product development | Metastasis | Antineoplastic agents
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Adjuvant Ovarian Suppression in Premenopausal Breast Cancer
by Francis, Prudence A and Regan, Meredith M and Fleming, Gini F and Láng, István and Ciruelos, Eva and Bellet, Meritxell and Bonnefoi, Hervé R and Climent, Miguel A and Da Prada, Gian Antonio and Burstein, Harold J and Martino, Silvana and Davidson, Nancy E and Geyer, Charles E and Walley, Barbara A and Coleman, Robert and Kerbrat, Pierre and Buchholz, Stefan and Ingle, James N and Winer, Eric P and Rabaglio-Poretti, Manuela and Maibach, Rudolf and Ruepp, Barbara and Giobbie-Hurder, Anita and Price, Karen N and Colleoni, Marco and Viale, Giuseppe and Coates, Alan S and Goldhirsch, Aron and Gelber, Richard D and Int Breast Canc Study Grp and SOFT Investigators and International Breast Cancer Study Group
The New England Journal of Medicine, ISSN 0028-4793, 01/2015, Volume 372, Issue 5, pp. 436 - 446
This trial did not support routine use of ovarian suppression in premenopausal breast cancer. Nevertheless, there may be some benefit from ovarian suppression... 
AMENORRHEA | MEDICINE, GENERAL & INTERNAL | THERAPY | YOUNG-WOMEN | CHEMOTHERAPY | Breast Neoplasms - surgery | Premenopause | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Breast Neoplasms - drug therapy | Antineoplastic Agents, Hormonal - adverse effects | Disease-Free Survival | Aromatase Inhibitors - adverse effects | Breast Neoplasms - radiotherapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Antineoplastic Agents, Hormonal - therapeutic use | Tamoxifen - therapeutic use | Mastectomy | Adult | Female | Androstadienes - therapeutic use | Chemotherapy, Adjuvant | Tamoxifen - adverse effects | Androstadienes - adverse effects | Aromatase Inhibitors - therapeutic use | Chemotherapy | Womens health | Invasiveness | Estrogen | Population studies | Breast cancer | Reproductive system | Tamoxifen | Drug therapy | Survival | Patients | Statistical analysis | Endocrine therapy | Radiation therapy | Cancer therapies | Survival analysis | Health risk assessment | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights